Cite
HARVARD Citation
Keam, B. et al. (2016). Optimal design and endpoint of clinical trials using immune checkpoint blocking agents. Expert review of anticancer therapy. 16 (12), pp. 1217-1218. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Keam, B. et al. (2016). Optimal design and endpoint of clinical trials using immune checkpoint blocking agents. Expert review of anticancer therapy. 16 (12), pp. 1217-1218. [Online].